Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Industry
|
| gptkbp:collaboratesWith |
universities
government agencies research institutions |
| gptkbp:contributedTo |
healthcare
|
| gptkbp:faced |
market competition
regulatory hurdles high R&D costs |
| gptkbp:focusesOn |
drug development
biotechnology research |
| gptkbp:hasCompetitors |
yes
|
| gptkbp:hasImpactOn |
economic growth
employment global health |
| https://www.w3.org/2000/01/rdf-schema#label |
Biopharmaceutical Industry
|
| gptkbp:includes |
biotechnology companies
pharmaceutical companies vaccines gene therapies cell therapies |
| gptkbp:isCharacterizedBy |
high investment
high risk of failure long development timelines |
| gptkbp:isEngagedIn |
yes
|
| gptkbp:isInfluencedBy |
market trends
technological advancements regulatory policies |
| gptkbp:isInvolvedIn |
clinical trials
market access regulatory affairs |
| gptkbp:isLinkedTo |
patient outcomes
public health initiatives healthcare_costs |
| gptkbp:isRated |
innovation
scientific advancements patient needs |
| gptkbp:isRegulatedBy |
gptkb:FDA
EMA |
| gptkbp:isSupportedBy |
venture capital
government funding public-private partnerships |
| gptkbp:isUsedIn |
yes
|
| gptkbp:isUtilizedFor |
medical research
healthcare advancements disease treatment |
| gptkbp:isUtilizedIn |
yes
|
| gptkbp:produces |
biopharmaceuticals
|
| gptkbp:utilizes |
genetic engineering
monoclonal antibodies cell culture |